Next Article in Journal
The Effects of Magnesium Supplementation on Subjective Anxiety and Stress—A Systematic Review
Previous Article in Journal
Tradeoff-in-the-Nephron: A Theory to Explain the Primacy of Phosphate in the Pathogenesis of Secondary Hyperparathyroidism
Article

Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis

1
Department of Orthopaedic Surgery, Shinshu University School of Medicine, Asahi 3-1-1, Matsumoto 390-8621, Japan
2
Department of Rheumatology, Toshin Yoshida Internal Medicine, Gomyo 643-2, Sakaki-Machi 389-0606, Japan
3
Department of Rheumatology, Marunouchi Hospital, Nagisa 1-7-45, Matsumoto 390-8601, Japan
*
Author to whom correspondence should be addressed.
Nutrients 2017, 9(5), 428; https://doi.org/10.3390/nu9050428
Received: 24 March 2017 / Revised: 16 April 2017 / Accepted: 21 April 2017 / Published: 26 April 2017
The aim of this 12-month retrospective study was to evaluate differences in the outcomes of denosumab alone or denosumab combined with vitamin D and calcium supplementation in patients having osteoporosis (OP) with rheumatoid arthritis (RA). Patients were divided into the denosumab monotherapy group (denosumab group, 22 cases) or denosumab plus vitamin D supplementation group (combination group, 21 cases). We measured serum bone alkaline phosphatase (BAP), N-terminal propeptide of type 1 collagen (P1NP), tartrate-resistant acid phosphatase (TRACP)-5b, and urinary N-terminal telopeptide of type-I collagen (NTX) at baseline, 1 week, and 1, 2, 4, 6, 8, and 12 months. We also assessed bone mineral density (BMD) of the lumbar 1-4 vertebrae (L-BMD) and bilateral total hips (H-BMD) at baseline and 4, 8, and 12 months. Matrix metalloprotanase-3 (MMP-3), Disease Activity Score-28 C-reactive protein (DAS28-CRP), Simplified Disease Activity Index (SDAI), and Health Assessment Questionnaire-Disability Index (HAQ-DI) were assessed before treatment and at 12 months to evaluate RA conditions. The study results showed that BAP, TRACP-5b, and NTX were significantly decreased, but tended to return to pre-treatment levels around 6 and 12 months in both groups. While L-BMD and H-BMD substantially increased in both groups, H-BMD had become significantly higher in the combination group at 12 months (p < 0.01) as compared with the denosumab group. There were no significant differences between the groups regarding MMP-3, DAS28-CRP, SDAI, or HAQ-DI. Compared with denosumab monotherapy, combination therapy of denosumab with vitamin D and calcium significantly increased H-BMD in patients having OP with RA. View Full-Text
Keywords: calcium; denosumab; osteoporosis; rheumatoid arthritis; vitamin D calcium; denosumab; osteoporosis; rheumatoid arthritis; vitamin D
Show Figures

Figure 1

MDPI and ACS Style

Nakamura, Y.; Suzuki, T.; Yoshida, T.; Yamazaki, H.; Kato, H. Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis. Nutrients 2017, 9, 428. https://doi.org/10.3390/nu9050428

AMA Style

Nakamura Y, Suzuki T, Yoshida T, Yamazaki H, Kato H. Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis. Nutrients. 2017; 9(5):428. https://doi.org/10.3390/nu9050428

Chicago/Turabian Style

Nakamura, Yukio, Takako Suzuki, Tomohiko Yoshida, Hideshi Yamazaki, and Hiroyuki Kato. 2017. "Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis" Nutrients 9, no. 5: 428. https://doi.org/10.3390/nu9050428

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop